Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6JKE

Discovery and the crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2.

6JKE の概要
エントリーDOI10.2210/pdb6jke/pdb
分子名称Bromodomain-containing protein 2, 7-chloranyl-2-[(3-chlorophenyl)amino]pyrano[3,4-e][1,3]oxazine-4,5-dione, SULFATE ION, ... (8 entities in total)
機能のキーワードbet family, bet inhibitor, bromodomain inhibitor, brd2-bd1 inhibitor, transcription
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数3
化学式量合計44485.61
構造登録者
Padmanabhan, B.,Mathur, S.,Deshmukh, P. (登録日: 2019-02-28, 公開日: 2020-07-01, 最終更新日: 2023-11-22)
主引用文献Deshmukh, P.,Mathur, S.,Gangadharan, G.,Krishnappa, G.,Dalavaikodihalli Nanjaiah, N.,Padmanabhan, B.
Novel pyrano 1,3 oxazine based ligand inhibits the epigenetic reader hBRD2 in glioblastoma.
Biochem.J., 477:2263-2279, 2020
Cited by
PubMed Abstract: Glioblastoma (GBM) is the most common primary brain malignancy, rarely amenable to treatment with a high recurrence rate. GBM are prone to develop resistance to the current repertoire of drugs, including the first-line chemotherapeutic agents with frequent recurrence, limiting therapeutic success. Recent clinical data has evidenced the BRD2 and BRD4 of the BET family proteins as the new druggable targets against GBM. In this relevance, we have discovered a compound (pyrano 1,3 oxazine derivative; NSC 328111; NS5) as an inhibitor of hBRD2 by the rational structure-based approach. The crystal structure of the complex, refined to 1.5 Å resolution, revealed that the NS5 ligand significantly binds to the N-terminal bromodomain (BD1) of BRD2 at the acetylated (Kac) histone binding site. The quantitative binding studies, by SPR and MST assay, indicate that NS5 binds to BD1 of BRD2 with a KD value of ∼1.3 µM. The cell-based assay, in the U87MG glioma cells, confirmed that the discovered compound NS5 significantly attenuated proliferation and migration. Furthermore, evaluation at the translational level established significant inhibition of BRD2 upon treatment with NS5. Hence, we propose that the novel lead compound NS5 has an inhibitory effect on BRD2 in glioblastoma.
PubMed: 32484211
DOI: 10.1042/BCJ20200339
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.5 Å)
構造検証レポート
Validation report summary of 6jke
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon